Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

STATUS

Recruiting
days left to enroll

13
participants needed

70
sponsor

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Send

Updated on 24 January 2021

See if I qualify

tubal ligation

prednisone

carcinoma

endocrine therapy

testosterone

metastasis

progressive disease

neutrophil count

hormone therapy

docetaxel

antiandrogen therapy

androgen suppression

bone scan

antiandrogens

orchiectomy

bone metastases

enzalutamide

testosterone level

serum testosterone

external beam radiation therapy

gonadotropin releasing hormone

infertility

androgen

adenocarcinoma

bone lesions

Summary

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

Open-label, randomized phase II trial in patients with symptomatic bone-only metastatic castration-resistant prostate cancer. Eligible patients are randomly assigned into two arms:

Arm A: radium-223 initially followed by docetaxel plus prednisone at the time of progression (the second step is optional according to clinical evolution of disease)
Arm B: docetaxel plus prednisone initially followed by radium-223 at the time of progression (the second step is optional according to clinical evolution of disease).

Description

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) Primary objective: To determine the effects of sequential treatment between radium-223 and docetaxel on the percentage of symptomatic bone-only CRPC patients experiencing improvement or worsening in health-related quality of life (HRQoL) Secondary objective: To compare survival in patients treated with sequential therapy between radium-223 and docetaxel and to identify predictive factors of Radium-223 for clinical outcome (progression free survival and overall survival) in this patient population.

Study Treatment:

Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection.

Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.

Statistical methodology A responder analysis investigating treatment effects on percentage of patients experiencing meaningful HRQoL improvement/worsening on treatment will be conducted. When defining meaningful improvement/worsening, the upper limit of the minimally important difference (MID) range will be used. The MIDs for FACT-P total score and subscales that will be used in this study will be 10 and 3, respectively.

Patients experiencing a QoL increase >=MID from baseline at week 12 will be considered responders while patients experiencing a decrease in HRQoL score >=MID at this time point will be considered to have experienced worsening HRQoL.

According to primary endpoint, considering a type I error 0.10, type II error 0.20, proportion of responder patients in the standard arm 0.10 and in the experimental arm of 0.40, a total of 70 patients (35 for each arm) will be enrolled in the study. Chi-square tests will be used to test for an association between treatment and meaningful improvement (i.e. responder) or worsening in HRQoL.

According to secondary endpoints, PFS, TPFS and OS will be estimated by the Kaplan-Meier method. The treatment groups will be compared with a two-sided log rank test. All analyses will be done in the intention-to-treat population. For translational studies, we will conduct a prognostic and predictive factor analysis for time-to-event clinical outcomes using a univariate Cox model; significant factors subsequently will be included in a multivariable Cox regression model (cutoff p<005).

Details

Condition	Metastatic Castration Resistant Prostate Cancer
Treatment	docetaxel, radium-223
Clinical Study Identifier	NCT03230734
Sponsor	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Last Modified on	24 January 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients must have histologically or cytologically confirmed adenocarcinoma of prostate
	Two or more bone metastases confirmed by bone scintigraphy within 4 weeks prior to study entry
	Symptomatic disease defined as regular use of opioid or non-opioid analgesic medication or treatment with external beam radiation therapy within the previous 12 weeks for cancer-related bone pain
	Known castration-resistant disease, defined according to the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria as: castrate serum testosterone level: 50 ng/dL (1.7 nmol/L)
	Subjects who have failed initial hormonal therapy, either by orchiectomy or by using a gonadotropin-releasing hormone (GnRH) agonist in combination with an anti-androgen, must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks
	Progressive disease based on prostate-specific antigen (PSA) and/or radiographic PCWG3
	criteria
	Serum PSA progression defined as two consecutive increases in PSA over a previous reference value within 6 months of first study treatment, each measurement at least one week apart. Serum PSA at screening 1ng/mL is the minimal starting value
	or radiographic disease progression based on documented bone lesions by the appearance of two or more new lesions by bone scintigraphy
	Patients who failed treatment with any Androgen deprivation therapy (ADT) abiraterone and/or enzalutamide for CRPC that must be terminated at least 4 weeks before study entry
	Male, aged 18 years
	Life expectancy of greater than 6 months
	Eastern Cooperative Oncology Group (ECOG) performance status2
	Patients must have normal organ and marrow function as defined below
	leukocytes >3,000 x 10 9/L
	absolute neutrophil count >1,500 x 10 9/L
	platelets >100,000 x 10 9/L
	total bilirubin within normal institutional limits
	aspartate aminotransferase (AST/SGOT)/alanine aminotransferase (ALT/SGPT) <2.5 X institutional upper limit of normal
	creatinine within normal institutional limits
	Male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 6 months after the last dose of radium-223 or docetaxel, according to guideline "Recommendation related to contraception and pregnancy testing in clinical trials", (2014_09_15 section 4.1) . Two acceptable methods of birth control thus include condom (barrier method of contraception) and one of the following is required (established use of oral, or injected or implanted hormonal method of contraception by the female partner; placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner; additional barrier method like occlusive cap with spermicidal foam/gel/film/cream/suppository in the female partner; tubal ligation in the female partner; vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy), for more than 6 months
	No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin)
	Participant is willing and able to give informed consent for participation in the study
Exclusion Criteria
	Patients who have had previous chemotherapy
	Patients who have had radiotherapy within 4 weeks prior to entering the study
	Participation in another clinical trial with any investigational agents within 30 days prior to study screening
	Concurrent use of other anticancer agents or treatments, with the following exceptions: luteinizing hormone-releasing hormone (LHRH) agonists or antagonists, denosumab or bisphosphonate (eg, zoledronic acid). Ongoing treatment should be kept at a stable schedule; however, if medically required, a change of dose, compound, or both is allowed
	Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
	Patients who received systemic radiotherapy (e.g. samarium, strontium etc.) for the treatment of bone metastases
	Patients who received blood transfusion or erythropoietin within the last 4 weeks prior to start of study treatment
	Patients who received prior treatment with Radium-223
	Patients with malignant lymphadenopathy exceeding 3 cm in short-axis diameter, or symptomatic nodal disease, i.e. scrotal, penile or leg edema
	Other primary tumor (other than CRPC) including hematological malignancy present within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)
	Maintenance treatment with corticosteroids corresponding to a prednisolone or prednisone dose above 10 mg/day. The dose must have been stable for at least 5 days
	Patients with imminent or established spinal cord compression based on clinical findings and/or magnetic resonance imaging
	Positive test for HIV
	Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
	Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen (anti-HBc) antibody test) are eligible
	Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

external beam radiation therapy

gonadotropin releasing hormone

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer